Maine LD1502 updates health insurance coverage for prostate cancer screening.
Maine LD1502 updates the requirements for health insurance coverage of prostate cancer screening. It expands the scope of required screening services to include medically necessary follow-up testing as directed by a physician, including urinary analysis, serum biomarker testing, and medical imaging such as magnetic resonance imaging. The bill prohibits the use of any deductible, copayment, coinsurance, or other cost-sharing requirement for the costs of services for the early detection of prostate cancer. The requirements apply to health plans issued or renewed on or after January 1, 2026.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.